Basit öğe kaydını göster

dc.contributor.authorÇakal, Beytullah
dc.contributor.authorÇakal, Sinem Deniz
dc.contributor.authorKaraca, Oǧuz
dc.contributor.authorOmaygenç, Mehmet Onur
dc.contributor.authorKızılırmak Yılmaz, Filiz
dc.contributor.authorGüneş, Hacı Murat
dc.contributor.authorÖzcan, Özgür Ulaş
dc.contributor.authorYıldırım, Arzu
dc.contributor.authorBoztosun, Bilal
dc.date.accessioned2021-02-12T06:44:09Z
dc.date.available2021-02-12T06:44:09Z
dc.date.issued2020en_US
dc.identifier.citationÇakal, B., Çakal, S. D., Karaca, O., Omaygenç, M. O., Kızılırmak Yılmaz, F., Güneş, H. M. ... Boztosun, B. (2020). Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients. Postepy w Kardiologii Interwencyjnej, 16(4), 391-398. https://dx.doi.org/10.5114/aic.2020.101763en_US
dc.identifier.issn1734-9338
dc.identifier.urihttps://dx.doi.org/10.5114/aic.2020.101763
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6554
dc.description.abstractIntroduction: Elevated risk of adverse events in comparison to metallic stents resulted in withdrawal of everolimus-eluting bioresorbable scaffolds (eBVS), known as the most intensively studied BVS. There is a paucity of data comparing the two different BVS. Aim: To evaluate the long-term clinical outcomes of the novolimus-eluting bioresorbable vascular scaffold (nBVS) compared with eBVS. Material and methods: Consecutive patients treated with nBVS or eBVS in our center were screened. The primary outcome was the 3-year rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and target-lesion revascularization (TLR). Results: After matching, 98 patients treated with 135 eBVS were compared with 98 patients treated with 136 nBVS. Baseline characteristics, clinical presentation, and lesion characteristics were comparable in both groups. The 3-year MACE rate was higher in the eBVS group (17.3% vs. 6.1%; p log-rank = 0.02). The occurrence of TLR (16.3% vs. 5.1%; p log-rank = 0.02) and TV-MI (8.2% vs. 0 %; p log-rank = 0.004) was also higher in the eBVS group except for cardiac deaths (1% vs. 2%; p log-rank = 0.98, eBVS vs. nBVS, respectively). Of note, definite device thrombosis rate was markedly increased in the eBVS group (5.1% vs. 0%; p log-rank = 0.03). Conclusions: The present study revealed that the 3-year event risk was lower for nBVS compared to eBVS. More evidence is needed to evaluate long-term performance of novolimus-eluting biovascular platforms.en_US
dc.language.isoengen_US
dc.publisherTermedia Publishing House Ltd.en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectCoronary Artery Diseaseen_US
dc.subjectPercutaneous Coronary Interventionen_US
dc.subjectBioresorbable Scaffoldsen_US
dc.titleLong-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patientsen_US
dc.typearticleen_US
dc.relation.ispartofPostepy w Kardiologii Interwencyjnejen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalıen_US
dc.authorid0000-0003-0230-6575en_US
dc.authorid0000-0003-2714-4584en_US
dc.authorid0000-0002-4281-0867en_US
dc.authorid0000-0003-2995-8792en_US
dc.authorid0000-0003-1919-3183en_US
dc.authorid0000-0001-5825-8627en_US
dc.authorid0000-0003-1516-1811en_US
dc.authorid0000-0002-4951-6716en_US
dc.identifier.volume16en_US
dc.identifier.issue4en_US
dc.identifier.startpage391en_US
dc.identifier.endpage398en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.5114/aic.2020.101763en_US
dc.identifier.wosqualityQ4en_US
dc.identifier.scopusqualityQ3en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess